10% excreted unchanged by the kidney hepatic dysfunction Glimepiride: (Amaryl) monotherapy -- once a day administration or in combination with insulin most potent -- lowest dose of the sulfonylureas long duration of action: half-life = 5 hours hepatic metabolism: complete to inactive products Secondary Failure and Tachyphylaxis to Sulfonylureas: Treatment failures occur Possibly due to pancreatic B cell refractoriness or to loss of dietary compliance Combination of sulfonylureas and insulin would appear justified only in the presence of severe insulin resistance Biguanides Metformin: (Glucophage) Proposed Mechanism of Action: glycolysis stimulation-- increased glucose removal from blood decreased hepatic gluconeogenesis decreased glucose absorption rate from the GI tract reduced plasma glucagon in patients with refractory obesity and insulin resistance Advantages: does not cause hypoglycemia does not increased weight May be used in combination with sulfonylureas when sulfonylurea monotherapy is not effective Toxic/adverse effects: most common -- gastrointestinal (20% frequency) anorexia, nausea, vomiting, diarrhea dose-related usually occurs upon initiation of therapy -- often transient in effect Decreased vitamin B12 absorption
Here, we demonstrated that OxLDL also promotes chronic mitochondrial dysfunction, which was prevented in macrophages overexpressing either mitochondrial or cytosolic GR
doi:10.1016/s1357-2725(97)00128-3 Carow, Berit, and Martin E Rottenberg
Store properly at room temperature, away from light and moisture
coli Trx 1, abcam), 400 nM (un)modified HpTpx, 200 M NADPH and 200 M H 2 O 2 in HEPESNaOH (50 mM, pH OF 7.0)
Solution conformation of the major adduct between the carcinogen (+)-anti-benzo[a]pyrene diol epoxide and DNA
